Pages that link to "Q27649316"
The following pages link to The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations (Q27649316):
Displaying 50 items.
- Proteopedia - a scientific 'wiki' bridging the rift between three-dimensional structure and function of biomacromolecules (Q21183903) (← links)
- A beta version of life: p110β takes center stage (Q24293200) (← links)
- Should individual PI3 kinase isoforms be targeted in cancer? (Q24309044) (← links)
- Twice upon a time: PI3K's secret double life exposed (Q24317406) (← links)
- Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions (Q24339544) (← links)
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy (Q24628724) (← links)
- The PI3K pathway as drug target in human cancer (Q24632283) (← links)
- Rapamycin and mTOR kinase inhibitors (Q24644623) (← links)
- Emerging common themes in regulation of PIKKs and PI3Ks (Q24647293) (← links)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (Q24656128) (← links)
- Will kinase inhibitors make it as glioblastoma drugs? (Q27012684) (← links)
- Phosphoinositides: tiny lipids with giant impact on cell regulation (Q27012953) (← links)
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (Q27015224) (← links)
- The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas (Q27021883) (← links)
- Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma (Q27026544) (← links)
- Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant (Q27320874) (← links)
- Structure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and Selectivity (Q27650628) (← links)
- A frequent kinase domain mutation that changes the interaction between PI3K and the membrane (Q27657679) (← links)
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors (Q27659013) (← links)
- Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein (Q27659586) (← links)
- Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34 (Q27660331) (← links)
- Structure of the iSH2 domain of human phosphatidylinositol 3-kinase p85β subunit reveals conformational plasticity in the interhelical turn region (Q27666219) (← links)
- Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases (Q27675831) (← links)
- Autoinhibition and Phosphorylation-Induced Activation of Phospholipase C-γ Isozymes (Q27678692) (← links)
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin (Q27684091) (← links)
- Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design (Q27684223) (← links)
- Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design (Q27684749) (← links)
- Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer (Q28076490) (← links)
- PI3K mutations in breast cancer: prognostic and therapeutic implications (Q28081992) (← links)
- PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data (Q28247338) (← links)
- Signaling by the phosphoinositide 3-kinase family in immune cells (Q28283677) (← links)
- S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton (Q28475032) (← links)
- Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data (Q28534371) (← links)
- Comprehensive assessment of cancer missense mutation clustering in protein structures (Q28606437) (← links)
- High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib (Q28818948) (← links)
- PI3K pathway alterations in cancer: variations on a theme (Q29615530) (← links)
- Targeting the phosphoinositide 3-kinase pathway in cancer (Q29615809) (← links)
- Targeting PI3K signalling in cancer: opportunities, challenges and limitations (Q29617685) (← links)
- Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer (Q30009083) (← links)
- PI3K and cancer: lessons, challenges and opportunities (Q30080017) (← links)
- Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity (Q30157667) (← links)
- The determinants of head and neck cancer: Unmasking the PI3K pathway mutations (Q30365726) (← links)
- Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach. (Q30371703) (← links)
- Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha (Q30437618) (← links)
- Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). (Q30538272) (← links)
- A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry (Q33476095) (← links)
- Statistical method on nonrandom clustering with application to somatic mutations in cancer (Q33522318) (← links)
- Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design (Q33653223) (← links)
- The PIK3CA gene as a mutated target for cancer therapy (Q33699378) (← links)
- Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. (Q33716552) (← links)